Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
No holdings reported for quarter Q1 2014 |
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
CTI Biopharmap Corp. | 24 | Q1 2023 | 14.8% |
APOLLO ENDOSURGERY INC | 23 | Q1 2023 | 15.6% |
XOMA CORP | 23 | Q2 2024 | 5.7% |
Cumberland Pharmaceuticals, Inc. | 19 | Q4 2020 | 7.0% |
Amarin Corp PLC - SPONS ADR | 14 | Q3 2022 | 23.2% |
VANDA PHARMACEUTICALS INC | 14 | Q3 2023 | 20.9% |
EVOLUS INC | 14 | Q2 2024 | 29.7% |
BIODELIVERY SCIENCES INTL | 14 | Q1 2020 | 12.9% |
EXAGEN INC | 14 | Q2 2024 | 4.6% |
ADMA BIOLOGICS INC | 13 | Q2 2024 | 19.2% |
View Stonepine Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Surrozen, Inc./DE | April 19, 2024 | 199,158 | 6.0% |
ALIMERA SCIENCES INC | February 13, 2024 | 5,373,732 | 10.0% |
aTYR PHARMA INC | February 13, 2024 | 482,258 | 0.8% |
AYTU BIOPHARMA, INC | February 13, 2024 | 565,484 | 10.0% |
DELCATH SYSTEMS, INC. | February 13, 2024 | 208,333 | 0.9% |
Evolus, Inc. | February 13, 2024 | 5,333,004 | 9.3% |
EXAGEN INC. | February 13, 2024 | 669,684 | 3.9% |
Gamida Cell Ltd. | February 13, 2024 | 3,000,000 | 2.2% |
IO Biotech, Inc. | February 13, 2024 | 3,641,345 | 5.4% |
Rezolute, Inc. | February 13, 2024 | 2,768,656 | 7.0% |
View Stonepine Capital Management, LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
N-PX | 2024-08-26 |
13F-HR/A | 2024-08-21 |
SC 13G | 2024-08-15 |
13F-HR | 2024-08-13 |
SC 13G | 2024-07-29 |
13F-HR | 2024-05-15 |
SC 13G | 2024-04-19 |
13F-HR | 2024-02-13 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
View Stonepine Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.